- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT01199289
A Study to Evaluate the Dosing of AMG 827 for Subjects With Inadequately Controlled Asthma
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Determine the Safety and Efficacy of AMG 827 in Subjects With Inadequately Controlled Asthma
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Studientyp
Einschreibung (Tatsächlich)
Phase
- Phase 2
Kontakte und Standorte
Studienorte
-
-
-
Bruxelles, Belgien
- Research Site
-
Leuven, Belgien
- Research Site
-
Liege, Belgien
- Research Site
-
-
-
-
-
Helsinki, Finnland
- Research Site
-
Jyväskylä, Finnland
- Research Site
-
Turku, Finnland
- Research Site
-
-
-
-
Alberta
-
Calgary, Alberta, Kanada
- Research Site
-
-
Ontario
-
Ottawa, Ontario, Kanada
- Research Site
-
Toronto, Ontario, Kanada
- Research Site
-
-
-
-
-
Bucheon-si, Korea, Republik von
- Research Site
-
Seoul, Korea, Republik von
- Research Site
-
Suwon, Korea, Republik von
- Research Site
-
-
-
-
-
Rotterdam, Niederlande
- Research Site
-
-
-
-
-
Bialystok, Polen
- Research Site
-
Chodziez, Polen
- Research Site
-
Gdansk, Polen
- Research Site
-
Wroclaw, Polen
- Research Site
-
-
-
-
-
Moscow, Russische Föderation
- Research Site
-
Saint Petersburg, Russische Föderation
- Research Site
-
-
-
-
-
Edeleny, Ungarn
- Research Site
-
Matrahaza, Ungarn
- Research Site
-
Tatabanya, Ungarn
- Research Site
-
Torokbalint, Ungarn
- Research Site
-
Zalaegerszeg - Pozva, Ungarn
- Research Site
-
-
-
-
California
-
Encinitas, California, Vereinigte Staaten
- Research Site
-
Huntington Beach, California, Vereinigte Staaten
- Research Site
-
Los Angeles, California, Vereinigte Staaten
- Research Site
-
San Diego, California, Vereinigte Staaten
- Research Site
-
Stockton, California, Vereinigte Staaten
- Research Site
-
-
Colorado
-
Colorado Springs, Colorado, Vereinigte Staaten
- Research Site
-
-
Georgia
-
Stockbridge, Georgia, Vereinigte Staaten
- Research Site
-
-
Maryland
-
Baltimore, Maryland, Vereinigte Staaten
- Research Site
-
-
Massachusetts
-
North Dartmouth, Massachusetts, Vereinigte Staaten
- Research Site
-
-
Missouri
-
Saint Louis, Missouri, Vereinigte Staaten
- Research Site
-
-
Montana
-
Bozeman, Montana, Vereinigte Staaten
- Research Site
-
-
Nebraska
-
Bellevue, Nebraska, Vereinigte Staaten
- Research Site
-
-
New Jersey
-
Skillman, New Jersey, Vereinigte Staaten
- Research Site
-
-
New York
-
Rockville Centre, New York, Vereinigte Staaten
- Research Site
-
-
North Carolina
-
High Point, North Carolina, Vereinigte Staaten
- Research Site
-
-
Ohio
-
Cincinnati, Ohio, Vereinigte Staaten
- Research Site
-
-
Oregon
-
Lake Oswego, Oregon, Vereinigte Staaten
- Research Site
-
Medford, Oregon, Vereinigte Staaten
- Research Site
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, Vereinigte Staaten
- Research Site
-
-
Texas
-
Dallas, Texas, Vereinigte Staaten
- Research Site
-
El Paso, Texas, Vereinigte Staaten
- Research Site
-
-
Wisconsin
-
Madison, Wisconsin, Vereinigte Staaten
- Research Site
-
-
-
-
-
Feldbach, Österreich
- Research Site
-
Hallein, Österreich
- Research Site
-
Wien, Österreich
- Research Site
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Men or women 18 to 65 years of age
- Percent of predicted FEV1 ≥ 50% and ≤ 80%
- At least 12% reversibility over pre-bronchodilator FEV1
- Inhaled corticosteroid (ICS) ≥ 200 and ≤ 1000 µg/day fluticasone powder or equivalent
- Ongoing asthma symptoms with ACQ composite score ≥ 1.5 points
Exclusion Criteria:
- Respiratory infection within 4 weeks of screening visit or 1 week of baseline visit
- History of chronic obstructive pulmonary disease or other chronic pulmonary condition other than asthma
- Any uncontrolled or clinically significant systemic disease (eg, uncontrolled diabetes, liver disease)
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Doppelt
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
---|---|
Placebo-Komparator: Placebo
Participants will receive the matching placebo administered as subcutaneous (SC) injections at Day 1 and weeks 1, 2, 4, 6, 8, and 10.
|
SC injection.
|
Experimental: AMG 827 140 mg
Participants will receive AMG 140 mg administered as SC injections at Day 1 and weeks 1, 2, 4, 6, 8, and 10.
|
SC injection.
|
Experimental: AMG 827 210 mg
Participants will receive AMG 210 mg administered as SC injections at Day 1 and weeks 1, 2, 4, 6, 8, and 10.
|
SC injection.
|
Experimental: AMG 827 280 mg
Participants will receive AMG 280 mg administered as SC injections at Day 1 and weeks 1, 2, 4, 6, 8, and 10.
|
SC injection.
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Change From Baseline in Asthma Control Questionnaire (ACQ) Composite Scores to Week 12
Zeitfenster: Baseline and Week 12
|
The ACQ is an instrument used in clinical research and practice to evaluate asthma control/impairment. It is a validated composite score that assesses disease control by evaluating 7 questions: night time awakenings, asthma symptoms upon awakening, activity limitation, shortness of breath, wheeze frequency, short-acting bronchodilator use, and forced expiratory volume in 1 second (FEV1). The response options for all these questions range from zero (no impairment/limitation) to six (total impairment/limitation) scale. The total score is obtained by adding the value from each question and dividing by the number of questions. Higher scores indicates worsening of condition and a negative change from baseline indicates improvement. |
Baseline and Week 12
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Change From Baseline in Pre- and Post-Bronchodilator Forced Expiratory Volume in 1 Second (FEV1)
Zeitfenster: Baseline and Week 12
|
FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.
FEV1 was performed both pre and post-administration of bronchodilator treatment at Baseline and Week 12.
|
Baseline and Week 12
|
Change From Baseline in AM and PM Peak Expiratory Flow Rate (PEFR) to Week 12
Zeitfenster: Baseline and Week 12
|
Baseline and Week 12
|
|
Change From Baseline in the Frequency of Rescue Short Acting β-Agonist (SABA) Use to Week 12
Zeitfenster: Baseline to Week 12
|
Participants recorded SABA use for 1 week prior to randomization (baseline) and the average number of days recorded was subtracted from average days of SABA use across 12 week intervention period.
|
Baseline to Week 12
|
Change From Baseline in Daily Asthma Symptom Score to Week 12
Zeitfenster: Baseline and Week 12
|
Participants recorded their daily asthma symptoms in their electronic diaries (Ediary). It included 7 questions: frequency of night time awakening, time awake at night, wheezing, shortness of breath, cough, chest tightness and activity limitation. Daily asthma symptoms score is the sum of 7 individual scores (with the total score ranging from 0-21). Higher scores indicates worsening of condition and a negative change from baseline indicates improvement. |
Baseline and Week 12
|
Change From Baseline in Asthma Quality of Life Questionnaire (AQLQ) Score at Week 12
Zeitfenster: Baseline and Week 12
|
The AQLQ is the most commonly used asthma specific instrument and includes evaluations of both symptom and quality of life measures. The 32-item instrument measures 4 domains affected by asthma including activity limitations, emotional function, exposure to environmental stimuli, and symptoms (Mitchell EA et al, 1997, Juniper et al, 1994, Christie MJ et al, 1993, Juniper et al, 1993). Participants were asked to recall their experiences during the last 2 weeks and to respond to each question on a 7-point scale (7=no impairment, 1=severe impairment). The overall score = mean of the responses to the 32 questions. Higher scores indicate "better quality of life" and a positive change from baseline indicates improved symptoms. |
Baseline and Week 12
|
Proportion of Asthma Symptom-free Days
Zeitfenster: Up to Week 12
|
Asthma symptom-free days were defined as a participant having a score of zero in their daily asthma symptom score. Asthma symptom-free days without SABA use were defined as a participant having a score of zero in their daily asthma symptom score and no SABA use. The proportion of asthma symptom-free days was calculated as the number of asthma symptom-free days over the number of days in the double-blind treatment period (12 weeks). |
Up to Week 12
|
Time to Maximum Observed Concentration (Tmax) of AMG 827 at Week 8 to 10
Zeitfenster: Week 8 (days 60 and 64), and pre-dose on Week 10
|
Week 8 (days 60 and 64), and pre-dose on Week 10
|
|
Maximum Observed Concentration (Cmax) of AMG 827 at Week 8 to 10
Zeitfenster: Week 8 (days 60 and 64), and pre-dose on Week 10
|
Week 8 (days 60 and 64), and pre-dose on Week 10
|
|
Area Under the Concentration-time Curve During the Dosing Interval (AUCtau) of AMG 827 at Week 8 to 10
Zeitfenster: Week 8 (days 60 and 64), and pre-dose on Week 10
|
Week 8 (days 60 and 64), and pre-dose on Week 10
|
Mitarbeiter und Ermittler
Sponsor
Publikationen und hilfreiche Links
Nützliche Links
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- 20090203
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Asthma
-
Vanderbilt University Medical CenterNoch keine RekrutierungAsthma bei Kindern | Asthmaanfall | Asthma akut | Akute Asthma-Exazerbation | Asthma; StatusVereinigte Staaten
-
Parc de Salut MarAktiv, nicht rekrutierendAsthma bei Kindern | Anhaltendes Asthma | Asthma-ExazerbationSpanien
-
University of California, San FranciscoAbgeschlossenAsthma bei Kindern | Asthmaanfall | Asthma akut | Asthma chronischVereinigte Staaten
-
Skane University HospitalSwedish Heart Lung FoundationAbgeschlossenAtemfunktionstests
-
SingHealth PolyclinicsNoch keine RekrutierungAsthma | Asthma bei Kindern | Asthmaanfall | Asthma akut | Asthma chronisch
-
Brunel UniversityKarolinska InstitutetUnbekanntBelastungsinduziertes AsthmaVereinigtes Königreich
-
Johann Wolfgang Goethe University HospitalAbgeschlossen
-
Universita di VeronaAbgeschlossen
-
Johann Wolfgang Goethe University HospitalRekrutierungHausstaubmilbenallergie | Belastungsinduziertes AsthmaDeutschland
-
Winthrop University HospitalAbgeschlossenBelastungsinduziertes AsthmaVereinigte Staaten
Klinische Studien zur Placebo
-
SamA Pharmaceutical Co., LtdUnbekanntAkute Bronchitis | Akute Infektion der oberen AtemwegeKorea, Republik von
-
National Institute on Drug Abuse (NIDA)AbgeschlossenCannabiskonsumVereinigte Staaten
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyAbgeschlossenMännliche Probanden mit Typ-II-Diabetes (T2DM)Deutschland
-
Texas A&M UniversityNutraboltAbgeschlossenGlucose and Insulin Response
-
Longeveron Inc.BeendetHypoplastisches LinksherzsyndromVereinigte Staaten
-
Instituto de Investigación Hospital Universitario...Creaciones Aromáticas Industriales, S.A. (CARINSA)Abgeschlossen
-
Soroka University Medical CenterAbgeschlossen
-
Regado Biosciences, Inc.AbgeschlossenGesunder FreiwilligerVereinigte Staaten
-
ItalfarmacoAbgeschlossenBecker-MuskeldystrophieNiederlande, Italien